naa a22 4500 51076326X CHVBK 20180411083147.0 cr unu---uuuuu 180411e20130601xx s 000 0 eng 10.1007/s12094-012-0954-4 doi (NATIONALLICENCE)springer-10.1007/s12094-012-0954-4 Safety and efficacy of metronomic non-pegylated liposomal encapsulated doxorubicin in heavily pretreated advanced breast cancer patients [Elektronische Daten] [L. Manso, N. Valdiviezo, J. Sepúlveda, E. Ciruelos, C. Mendiola, I. Ghanem, E. Vega, R. Manneh, M. Dorta, H. Cortés-Funes] Purpose: Metronomic administration of the same chemotherapy agents (lower doses with closer intervals) may optimize their antiangiogenic properties. The aim of our study was to determine the efficacy and safety of a metronomic regimen based in non-pegylated liposomal doxorubicin (NPLD) in advanced breast cancer patients. Methods: Clinical records of patients with pretreated advanced breast cancer and who were treated with the Metronomic-Cooper-type regimen consisting of weekly fixed doses of NPLD (30mg IV) plus 5-Fluorouracil (5-FU) (500mg IV) plus vincristine (0.25mg IV) and daily oral cyclophosphamide (50mg) plus prednisone (20mg) were reviewed. Results: In 84 pretreated patients, a tumor response was observed in 38 patients (45%); stable disease was observed in 23 patients (27%). Median progression-free survival (PFS) time to progression was 8.4months and median overall survival (OS) was 21months. The most common grade 2-3 hematologic adverse event was neutropenia, which was observed in 47 patients (56%). Febrile neutropenia was observed in 10 patients (12%). The most common non-hematologic adverse events were asthenia and mucositis which were observed in 60 patients (71%) and 26 patients (31%), respectively. Three patients (4%) experienced an asymptomatic decline of the left ventricular ejection fraction. Conclusions: NPLD-based metronomic regimen was effective and safe in pretreated advanced breast cancer patients. It could be considered as an appealing option to treat patients previously exposed to anthracyclines. Federación de Sociedades Españolas de Oncología (FESEO), 2012 Non-pegylated liposomal doxorubicin nationallicence Breast cancer nationallicence Anthracyclines nationallicence Metronomic-Cooper-type chemotherapy nationallicence Manso L. Medical Oncology Service, Hospital Universitario 12 de Octubre, Avda de Córdoba s/n, 28041, Madrid, Spain aut Valdiviezo N. Medical Oncology Service, Hospital Universitario 12 de Octubre, Avda de Córdoba s/n, 28041, Madrid, Spain aut Sepúlveda J. Medical Oncology Service, Hospital Universitario 12 de Octubre, Avda de Córdoba s/n, 28041, Madrid, Spain aut Ciruelos E. Medical Oncology Service, Hospital Universitario 12 de Octubre, Avda de Córdoba s/n, 28041, Madrid, Spain aut Mendiola C. Medical Oncology Service, Hospital Universitario 12 de Octubre, Avda de Córdoba s/n, 28041, Madrid, Spain aut Ghanem I. Medical Oncology Service, Hospital Universitario 12 de Octubre, Avda de Córdoba s/n, 28041, Madrid, Spain aut Vega E. Medical Oncology Service, Hospital Universitario 12 de Octubre, Avda de Córdoba s/n, 28041, Madrid, Spain aut Manneh R. Medical Oncology Service, Hospital Universitario 12 de Octubre, Avda de Córdoba s/n, 28041, Madrid, Spain aut Dorta M. Medical Oncology Service, Hospital Universitario 12 de Octubre, Avda de Córdoba s/n, 28041, Madrid, Spain aut Cortés-Funes H. Medical Oncology Service, Hospital Universitario 12 de Octubre, Avda de Córdoba s/n, 28041, Madrid, Spain aut Clinical and Translational Oncology Springer Milan 15/6(2013-06-01), 467-471 1699-048X 15:6<467 2013 15 12094 https://doi.org/10.1007/s12094-012-0954-4 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-012-0954-4 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Manso L. Medical Oncology Service, Hospital Universitario 12 de Octubre, Avda de Córdoba s/n, 28041, Madrid, Spain aut NATIONALLICENCE 700 1- Valdiviezo N. Medical Oncology Service, Hospital Universitario 12 de Octubre, Avda de Córdoba s/n, 28041, Madrid, Spain aut NATIONALLICENCE 700 1- Sepúlveda J. Medical Oncology Service, Hospital Universitario 12 de Octubre, Avda de Córdoba s/n, 28041, Madrid, Spain aut NATIONALLICENCE 700 1- Ciruelos E. Medical Oncology Service, Hospital Universitario 12 de Octubre, Avda de Córdoba s/n, 28041, Madrid, Spain aut NATIONALLICENCE 700 1- Mendiola C. Medical Oncology Service, Hospital Universitario 12 de Octubre, Avda de Córdoba s/n, 28041, Madrid, Spain aut NATIONALLICENCE 700 1- Ghanem I. Medical Oncology Service, Hospital Universitario 12 de Octubre, Avda de Córdoba s/n, 28041, Madrid, Spain aut NATIONALLICENCE 700 1- Vega E. Medical Oncology Service, Hospital Universitario 12 de Octubre, Avda de Córdoba s/n, 28041, Madrid, Spain aut NATIONALLICENCE 700 1- Manneh R. Medical Oncology Service, Hospital Universitario 12 de Octubre, Avda de Córdoba s/n, 28041, Madrid, Spain aut NATIONALLICENCE 700 1- Dorta M. Medical Oncology Service, Hospital Universitario 12 de Octubre, Avda de Córdoba s/n, 28041, Madrid, Spain aut NATIONALLICENCE 700 1- Cortés-Funes H. Medical Oncology Service, Hospital Universitario 12 de Octubre, Avda de Córdoba s/n, 28041, Madrid, Spain aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/6(2013-06-01), 467-471 1699-048X 15:6<467 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer